Author(s): Erzurum SC, Gaston BM, Erzurum SC, Gaston BM
Abstract Share this page
Abstract Diagnosis and treatment of asthma are currently based on assessment of patient symptoms and physiologic tests of airway reactivity. Research over the past decade has identified an array of biochemical and cellular biomarkers, which reflect the heterogeneous and multiple mechanistic pathways that may lead to asthma. These mechanistic biomarkers offer hope for optimal design of therapies targeting the specific pathways that lead to inflammation. This article provides an overview of blood, urine, and airway biomarkers; summarizes the pathologic pathways that they signify; and begins to describe the utility of biomarkers in the future care of patients with asthma. Copyright © 2012 Elsevier Inc. All rights reserved.
This article was published in Clin Chest Med
and referenced in Journal of Environmental & Analytical Toxicology